FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Charles Blanke

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Daniel J Renouf; Caroline Speers; Diego Villa; Charles D Blanke; Sharlene Gill; Howard J Lim; Susan E O'Reilly; Hagen Kennecke
Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
Charles D Blanke; Richard M Goldberg; Axel Grothey; Neal J Meropol; Margaret Mooney; Nancy Roach; Leonard B Saltz; John J Welch; William A Wood
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.
Philip J Gold; Bryan Goldman; Syma Iqbal; Lawrence P Leichman; Wu Zhang; Heinz-Josef Lenz; Charles D Blanke
Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Charles Blanke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Daniel J Renouf; Caroline Speers; Diego Villa; Charles D Blanke; Sharlene Gill; Howard J Lim; Susan E O'Reilly; Hagen Kennecke
Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
Clinical colorectal cancer 2011;10(2):97-101.
2011: Charles D Blanke; Richard M Goldberg; Axel Grothey; Neal J Meropol; Margaret Mooney; Nancy Roach; Leonard B Saltz; John J Welch; William A Wood
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.
The oncologist 2011;16(8):1061-8.
2010: Philip J Gold; Bryan Goldman; Syma Iqbal; Lawrence P Leichman; Wu Zhang; Heinz-Josef Lenz; Charles D Blanke
Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(9):1472-6.
2010: Carol M Moinpour; Nancy L Vaught; Bryan Goldman; Mary W Redman; Philip A Philip; Barbara Millwood; Scott M Lippman; Thomas E Seay; Patrick J Flynn; Eileen O'Reilly; Kendrith M Rowland; Ralph P Wong; Jacqueline K Benedetti; Charles D Blanke
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(22):3611-6.
2010: Charles D Blanke; Kari Chansky; Kathy L Christman; Scott A Hundahl; Brian F Issell; Peter J Van Veldhuizen; G Thomas Budd; James L Abbruzzese; John S Macdonald
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
American journal of clinical oncology 2010;33(2):117-20.
2010: Aimery de Gramont; Joleen Hubbard; Qian Shi; Michael J O'Connell; Marc Buyse; Jacqueline K Benedetti; Brian Bot; Chris O'Callaghan; Greg Yothers; Richard M Goldberg; Charles D Blanke; Al Benson; Qiqi Deng; Steven R Alberts; Thierry Andre; Norman Wolmark; Axel Grothey; Daniel Sargent
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):460-5.
2010: Charles D Blanke; Daniel M Huse
Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Journal of medical economics 2010;13(4):681-90.
2009: Robert P Whitehead; Cathryn Rankin; Paulo M G Hoff; Philip J Gold; Kevin G Billingsley; Robert A Chapman; Lucas Wong; John H Ward; James L Abbruzzese; Charles D Blanke
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
Investigational new drugs 2009;27(5):469-75.
2009: Charles D Blanke
Biomarkers in GIST: partly ready for prime-time use.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5603-5.
2009: Daniel Renouf; Jean-Yves Blay; Charles D Blanke
Accomplishments in 2008 in the management of gastrointestinal stromal tumors.
Gastrointestinal cancer research : GCR 2009;3(5 Supplement 2):S67-72.
2009: Lori Rink; Yuliya Skorobogatko; Andrew V Kossenkov; Martin G Belinsky; Thomas Pajak; Michael C Heinrich; Charles D Blanke; Margaret von Mehren; Michael Ochs; Burton Eisenberg; Andrew K Godwin
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
Molecular cancer therapeutics 2009;8(8):2172-82.
2009: Charles D Blanke; Tomasz M Beer; K Todd; Motomi Mori; M Stone; Charles D Lopez
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer.
Investigational new drugs 2009;27(4):374-8.
2009: George D Demetri; Yanfeng Wang; Elisabeth Wehrle; Amy Racine; Zariana Nikolova; Charles D Blanke; Heikki Joensuu; Margaret von Mehren
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3141-7.
2009: Daniel J Renouf; Lora Wilson; Charles D Blanke
Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):3908-11.
2009: Ronald P DeMatteo; Karla V Ballman; Cristina R Antonescu; ROBERT G MAKI; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D Mccarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Lancet 2009;373(9669):1097-104.
2009: Charles D Blanke
Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):655-8.
2009: Gustavo dos Santos Fernandes; Charles D Blanke; Daniela Freitas; Rodrigo Guedes; Paulo M Hoff
Perioperative treatment of gastrointestinal stromal tumors.
Oncology (Williston Park, N.Y.) 2009;23(1):54-61.
2009: Burton L Eisenberg; Jonathan Harris; Charles D Blanke; George D Demetri; Michael C Heinrich; James C Watson; John P Hoffman; Scott Okuno; John M Kane; Margaret von Mehren
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
Journal of surgical oncology 2009;99(1):42-7.
2008: Michael C Heinrich; Kouros Owzar; Christopher L Corless; Donna Hollis; Ernest C Borden; Christopher D M Fletcher; Christopher W Ryan; Margaret von Mehren; Charles D Blanke; Cathryn Rankin; Robert S Benjamin; Vivien H C Bramwell; George D Demetri; Monica M Bertagnolli; Jonathan A Fletcher
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(33):5360-7.
2008: Joseph Chan; Cary O Harding; Charles D Blanke
Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency.
Southern medical journal 2008;101(5):543-5.
2008: Charles D Blanke
Perforation and Stage-II Colon Cancer: Is it Always High Risk?
Gastrointestinal cancer research : GCR 2008;2(2):103-4.
2008: Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; ROBERT G MAKI; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):626-32.
2008: Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton L Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):620-5.
2008: Maryclare Sarff; Wendy Rogers; Charles D Blanke; John T Vetto
Evaluation of the tumor board as a Continuing Medical Education (CME) activity: is it useful?
Journal of cancer education : the official journal of the American Association for Cancer Education 2008;23(1):51-6.
2007: Carmen Allegra; Charles D Blanke; Marc Buyse; Richard M Goldberg; Axel Grothey; Neal J Meropol; Leonard B Saltz; Alan P Venook; Greg Yothers; Daniel Sargent
End points in advanced colon cancer clinical trials: a review and proposal.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3572-5.
2007: George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; ROBERT G MAKI; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5 Suppl 2():S1-29; quiz S30.
2007: Abbas Agaimy; Antje-Friederike Pelz; Christopher L Corless; Peter H Wünsch; Michael C Heinrich; Ferdinand Hofstaedter; Wolfgang Dietmaier; Charles D Blanke; Peter Wieacker; Albert Roessner; Arndt Hartmann; Regine Schneider-Stock
Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization.
Oncology reports 2007;18(1):9-15.
2007: Alan P Venook; Charles D Blanke; Donna Niedzwiecki; Heinz-Josef Lenz; John R Taylor; Donna R Hollis; Susan Sutherland; Richard M Goldberg
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
Clinical colorectal cancer 2007;6(7):536-8.
2007: Dong W Kim; Charles D Blanke; Huiyun Wu; Yu Shyr; Jordan Berlin; R Daniel Beauchamp; Bapsi Chakravarthy
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
International journal of radiation oncology, biology, physics 2007;67(2):397-404.
2007: Richard M Goldberg; Mace L Rothenberg; Eric Van Cutsem; Al B Benson; Charles D Blanke; Robert B Diasio; Axel Grothey; Heinz-Josef Lenz; Neal J Meropol; Ramesh K Ramanathan; Carlos H Roberto Becerra; Rita Wickham; Delma Armstrong; Carol Viele
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
The oncologist 2007;12(1):38-50.
2007: Daniel M Huse; Margaret von Mehren; Gregory Lenhart; Heikki Joensuu; Charles D Blanke; Weiwei Feng; Stan Finkelstein; George D Demetri
Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
Clinical drug investigation 2007;27(2):85-93.
2006: Ian Schnadig; Charles D Blanke
Gastrointestinal stromal tumors: imatinib and beyond.
Current treatment options in oncology 2006;7(6):427-37.
2006: Tomislav Dragovich; Sheryl McCoy; Cecilia Fenoglio-Preiser; Jiang Wang; Jacqueline K Benedetti; Amanda F Baker; Christopher B Hackett; Susan G Urba; Ken S Zaner; Charles D Blanke; James L Abbruzzese
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4922-7.
2006: Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(29):4764-74.
2006: Maneesh Gupta; Brett C Sheppard; Christopher L Corless; Karen R MacDonell; Charles D Blanke; Kevin G Billingsley
Outcome following surgical therapy for gastrointestinal stromal tumors.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2006;10(8):1099-105.
2006: Charles D Blanke
Current and future management of GIST.
Clinical advances in hematology & oncology : H&O 2006;4(8):582-3.
2006: Stephen K Williamson; Sheryl A McCoy; David R Gandara; Shaker R Dakhil; Kathleen J Yost; Jorge C Paradelo; James N Atkins; Charles D Blanke; James L Abbruzzese
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
American journal of clinical oncology 2006;29(2):116-22.
2006: Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Sylvie Bonvalot; Burton Eisenberg
Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
The oncologist 2006;11(1):9-20.
2006: Joseph M Unger; Charles A Coltman; John J Crowley; Laura F Hutchins; Silvana Martino; Robert B Livingston; John S Macdonald; Charles D Blanke; David R Gandara; E David Crawford; Kathy S Albain
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):141-4.
2005: Daniel J Sargent; H Samuel Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery de Gramont
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(34):8664-70.
2005: Alan P Venook; Charles D Blanke; Donna Niedzwiecki; Heinz-Josef Lenz; John R Taylor; Donna R Hollis; Susan Sutherland; Richard M Goldberg
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
Clinical colorectal cancer 2005;5(4):292-4.
2005: Charles D Blanke; Burton L Eisenberg; Michael C Heinrich
Epidemiology of GIST.
The American journal of gastroenterology 2005;100(10):2366.
2005: Charles D Blanke
Gefitinib in colorectal cancer: if wishes were horses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5446-9.
2005: Rachel Sanborn; Charles D Blanke
Gastrointestinal stromal tumors and the evolution of targeted therapy.
Clinical advances in hematology & oncology : H&O 2005;3(8):647-57.
2005: Charles D Blanke
Whither irinotecan?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4811-4.
2005: Karen L Tedesco; Jordan Berlin; Charles D Blanke; Ming Teng; Hak Choy; John Roberts; R Daniel Beauchamp; Steven D Leach; Ken Wyman; John L Tarpley; Yu Shyr; Carol Caillouette; Bapsi Chakravarthy
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
International journal of radiation oncology, biology, physics 2005;61(5):1364-70.
2005: Charles D Blanke
Low dose versus high dose imatinib for gastrointestinal stromal tumors.
Nature clinical practice. Gastroenterology & hepatology 2005;2(2):76-7.
2005: Rachel Sanborn; Charles D Blanke
Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
Seminars in oncology 2005;32(1):69-75.
2005: Charles D Blanke; Christopher L Corless
State-of-the art therapy for gastrointestinal stromal tumors.
Cancer investigation 2005;23(3):274-80.
2005: Charles D Blanke; Nora Mattek; Thomas G Deloughery; Dennis R Koop
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
Prostaglandins & other lipid mediators 2005;75(1-4):169-72.
2004: Rowena N Schwartz; Charles D Blanke; Larry John Pesko
Targeted therapies in the treatment of colorectal cancer: what managed care needs to know.
Journal of managed care pharmacy : JMCP 2004;10(5 Suppl B):S2-13; quiz S14-7.
2004: Charles D Blanke
Current management of GIST.
Clinical advances in hematology & oncology : H&O 2004;2(5):280, 283.
2004: Petri Bono; Andreas Krause; Margaret von Mehren; Michael C Heinrich; Charles D Blanke; Sasa Dimitrijevic; George D Demetri; Heikki Joensuu
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.
Blood 2004;103(8):2929-35.
2004: Charles D Blanke
Role of COX-2 inhibitors in cancer therapy.
Cancer investigation 2004;22(2):271-82.
2003: Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton L Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4342-9.
2003: J Randolph Hecht; Charles D Blanke; Al B Benson; Heinz J Lenz
Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.
Oncology (Williston Park, N.Y.) 2003;17(9 Suppl 8):13-5.
2003: Brandon Hayes-Lattin; Charles D Blanke; Thomas G Deloughery
Pulmonary and intracerebral plasmacytomas in a patient without multiple myeloma: a case report.
American journal of hematology 2003;73(2):131-4.
2003: Gregory A Masters; Lieven Declerck; Charles D Blanke; Alan B Sandler; Russell F DeVore; Kathy D Miller; David Johnson
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1550-5.
2003: Charles D Blanke; Jaime L Masferrer
Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trials.
Progress in experimental tumor research 2003;37():243-60.
2002: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton L Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos J Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher L Corless; Christopher D M Fletcher; Heikki Joensuu
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
The New England journal of medicine 2002;347(7):472-80.
2002: Tara Karamlou; John T Vetto; Christopher L Corless; Thomas G Deloughery; Douglas O Faigel; Charles D Blanke
Metastatic breast cancer manifested as refractory anemia and gastric polyps.
Southern medical journal 2002;95(8):922-5.
2002: Kevin W H Yee; Brett C Sheppard; John S Domreis; Charles D Blanke
Cancers of the gallbladder and biliary ducts.
Oncology (Williston Park, N.Y.) 2002;16(7):939-46, 949; discussion 949-50, 952-3, 956-7.
2002: Charles D Blanke
Celecoxib with chemotherapy in colorectal cancer.
Oncology (Williston Park, N.Y.) 2002;16(4 Suppl 3):17-21.
2002: Michael C Heinrich; Charles D Blanke; Brian J Druker; Christopher L Corless
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1692-703.
2002: Cornelis J A Punt; Charles D Blanke; J Zhang; Luz D Hammershaimb
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(1):92-4.
2002: Charles D Blanke; J Shultz; J Cox; M Modiano; R Isaacs; B Kasimis; Richard L Schilsky; J Fleagle; M Moore; Nancy Kemeny; David A Carlin; Luz D Hammershaimb; D Haller
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(1):87-91.
2001: Charles D Blanke; B L Eisenberg; Michael C Heinrich
Gastrointestinal stromal tumors.
Current treatment options in oncology 2001;2(6):485-91.
2001: Charles D Blanke; D G Haller; A B Benson; Mace L Rothenberg; Jordan Berlin; Motomi Mori; Y C Hsieh; L L Miller
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(11):1575-80.
2001: Charles D Blanke; M Stipanov; J Morrow; M Rothenberg; Rebecca Chinery; Yu Shyr; R Coffey; D H Johnson; Steven D Leach; R Daniel Beauchamp
A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies.
Investigational new drugs 2001;19(1):21-7.
2000: Leonard B Saltz; J V Cox; Charles D Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; Paula K Locker; Nicoletta Pirotta; Gary L Elfring; Langdon L Miller
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
The New England journal of medicine 2000;343(13):905-14.
2000: Charles D Blanke; M P Hemmer; R S Witte
Acute tumor lysis syndrome with choriocarcinoma.
Southern medical journal 2000;93(9):916-9.
2000: W John; Joel Picus; Charles D Blanke; jeffrey clark; L N Schulman; eric rowinsky; D E Thornton; Patrick J Loehrer
Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study.
Cancer 2000;88(8):1807-13.
2000: Kathy D Miller; Joel Picus; Charles D Blanke; W John; J Clark; Larry N Shulman; D Thornton; eric rowinsky; Patrick J Loehrer
Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(1):101-3.
1999: Mace L Rothenberg; Charles D Blanke
Topoisomerase I inhibitors in the treatment of colorectal cancer.
Seminars in oncology 1999;26(6):632-9.
1999: Charles R Scoggins; Ingrid M Meszoely; Charles D Blanke; R Daniel Beauchamp; Steven D Leach
Nonoperative management of primary colorectal cancer in patients with stage IV disease.
Annals of surgical oncology 1999;6(7):651-7.
1999: Charles D Blanke; Ming Teng; Hak Choy
The role of UFT in combined-modality therapy.
Oncology (Williston Park, N.Y.) 1999;13(10 Suppl 5):47-54.
1999: N R Dickson; BP Nicholson; Kenneth R Hande; Charles D Blanke; D Johnson; A Cohen
Paclitaxel, UFT, and calcium folinate in metastatic breast cancer.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):69-70.
1999: DM Rose; William C Chapman; A T Brockenbrough; J Kelly Wright; AT Rose; Steven G Meranze; Murray J Mazer; TK Blair; Charles D Blanke; Jacob P Debelak; C Wright Pinson
Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma.
American journal of surgery 1999;177(5):405-10.
1999: Charles D Blanke; Hak Choy; Ming Teng; R Daniel Beauchamp; Steven D Leach; J Roberts; K Washington; D H Johnson
Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer.
Seminars in radiation oncology 1999;9(2 Suppl 1):43-52.
1998: AT Rose; DM Rose; C Wright Pinson; J Kelly Wright; TK Blair; Charles D Blanke; Dominique Delbeke; Jacob P Debelak; William C Chapman
Hepatocellular carcinoma outcomes based on indicated treatment strategy.
The American surgeon 1998;64(12):1128-34; discussion 1134-5.
1998: Kay Washington; A Chiappori; K Hamilton; Yu Shyr; Charles D Blanke; D Johnson; JL Sawyers; DR Beauchamp
Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1998;11(9):805-13.
1998: Alan B Sandler; Charles D Blanke; F Monaco; M A Carey; R Ansari; B Fisher; C H Spiridonidis; Lawrence Einhorn; Craig Nichols
CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: a Hoosier Oncology Group phase II trial.
American journal of clinical oncology 1998;21(3):294-7.
1998: Steven J Hoff; JL Sawyers; Charles D Blanke; Hak Choy; J R Stewart
Prognosis of adenocarcinoma arising in Barrett's esophagus.
The Annals of thoracic surgery 1998;65(1):176-80; discussion 180-1.
1997: S C Taplin; Charles D Blanke; C Baughman
Nursing care strategies for the management of side effects in patients treated for colorectal cancer.
Seminars in oncology 1997;24(5 Suppl 18):S18-64-S18-70.
1997: Charles D Blanke; M Messenger; S C Taplin
Trimetrexate: review and current clinical experience in advanced colorectal cancer.
Seminars in oncology 1997;24(5 Suppl 18):S18-57-S18-63.
1997: Charles D Blanke; S C Delgalvis; G R Nichols
Late recurrence of seminoma.
Southern medical journal 1997;90(6):653-5.
1997: Charles D Blanke; B Kasimis; P Schein; R Capizzi; M Kurman
Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):915-20.
1997: Charles D Blanke; David H Johnson
Treatment of small cell lung cancer.
Seminars in thoracic and cardiovascular surgery 1997;9(1):101-10.
1997: Charles D Blanke; Russell F DeVore; Yu Shyr; B Epstein; M Murray; Kenneth R Hande; S Stewart; D Johnson
A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer.
International journal of radiation oncology, biology, physics 1997;37(1):111-6.
1996: Charles D Blanke; P J Loehrer; Craig Nichols; L H Einhorn
A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors.
American journal of clinical oncology 1996;19(5):487-91.
1996: David H Johnson; D M Paul; Kenneth R Hande; Yu Shyr; Charles D Blanke; B Murphy; M Lewis; R F De Vore
Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):2054-60.
1995: Charles D Blanke; C Clark; E R Broun; Guido Tricot; I Cunningham; Kenneth Cornetta; A Hedderman; Robert Hromas
Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections.
The American journal of medicine 1995;99(3):326-8.
1995: Charles D Blanke; Rafat H Ansari; R Mantravadi; R Gonin; R Tokars; W Fisher; K Pennington; T O'Connor; S Rynard; M Miller
Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1425-9.
1995: Charles D Blanke; David H Johnson
Combined modality therapy in non-small cell lung cancer.
Current opinion in oncology 1995;7(2):144-9.
1994: Robert Hromas; C Clark; Charles D Blanke; Guido Tricot; Kenneth Cornetta; A Hedderman; E R Broun
Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation.
Bone marrow transplantation 1994;14(4):663-4.
1994: Robert Hromas; Kenneth Cornetta; Edward F Srour; Charles D Blanke; E R Broun
Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation.
Blood 1994;84(5):1689-90.